Attempted passive prophylaxis with a monoclonal anti-Burkholderia pseudomallei exopolysaccharide antibody in a murine model of melioidosis

Immunopharmacology and Immunotoxicology

Volumn 27, Issue 4, 2005, Pages 565-583

  Bottex, Chantal ^a   Gauthier, Yves P ^a   Hagen, Ralf M ^b   Finke, Ernst J ^b   Splettstösser, Wolf D ^b   Thibault, François M ^a   Neubauer, Heinrich ^b   Vidal, Dominique R ^a  

^a CENTRE DE RECHERCHES   (France)

^b BUNDESWEHR INSTITUTE OF MICROBIOLOGY   (Germany)

Author keywords

Burkholderia pseudomallei; Immunomodulation; Melioidosis; Monoclonal antibody; Prophylaxis

Indexed keywords

BACTERIAL VACCINE; EXOPOLYSACCHARIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PS6F6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; GRAM NEGATIVE INFECTION; HUMORAL IMMUNITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RESISTANCE; MELIOIDOSIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BURKHOLDERIA PSEUDOMALLEI; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; INTERFERON TYPE II; INTERLEUKIN-12; MELIOIDOSIS; MICE; POLYSACCHARIDES, BACTERIAL; SPLEEN; SURVIVAL RATE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI; MURINAE; NEGIBACTERIA;

EID: 32344432266     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970500493995     Document Type: Article

References (59)

1. Dance, D.A.B. Pseudomonas pseudomallei: danger in the paddy fields. Trans. R. Soc. Trop. Med. Hyg. 1991, 85, 1-3.
2. Dance, D.A.B.; King, C.; Aucken, H.; Knott, C.D.; West, P.G.; Pitt, T.L. An outbreak of melioidosis in imported primates in Britain. Vet. Record. 1992, 130, 525-529.
3. Dance, D.A.B.; Smith, M.D.; Aucken, H.; Pitt, T.L Imported melioidosis in England and Wales. Lancet 1999, 353, 208.
4. Mollaret, H.H. L'affaire du jardin des plantes ou comment la mélioïdose fit son apparition en France. Med. Mal. Infect. 1988, 18, 643-654.
5. Torrens, J.K.; McWhinney, P.H.; Tompkin, D.S. A deadly thorn: a case of importated melioidosis. Lancet, 1999, 353, 1016.
6. Dance, D.A.B. Melioidosis: the tip of the iceberg. Clin. Microbiol. Rev. 1991, 4, 52-60.
7. Woods, D.E.; DeShazer, D.; Moore, R.A.; Brett, P.J.; Burtnick, M.N.; Reckseidler, S.L.; Senkiw, M.D. Current studies on the pathogenesis of melioidosis. Microbes Infect 1999, 2, 157-162.
8. Centers for Disease Control and Prevention. Division of Bacterial and Mycotic Diseases: disease information, melioidosis. [Online.].
9. . Mays, E.E.; Ricketts, E.A. Melioidosis: recrudescence associated with bronchiogenic carcinoma twenty-six years following initial geographic exposure. Chest 1975, 68, 261-263.
10. Chaowagul, W.; Supputamongkol, Y.; Dance, D.A.B.; Rajchanuvong, A.; Pattaraarechachai, J.; White, N. J. Relapse in melioidosis: incidence and risk factors. J. Infect. Dis. 1993, 168, 1181-1185.
11. White, N.J.; Dance, D.A.B.; Chaowagul, W.; Wattanagoon, Y.; Wuthiekanum, V.; Pitakwatchara, N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989, ii, 697-702.
12. Harley, V. S.; Dance, D. A. B.; Tovey, G.; McCrossan, M. V.; Drasar, B. S. An ultrasructural study of the phagocytosis of Burkholderia pseudomallei. Microbios 1998, 94, 35-45.
13. Harley, V.S.; Dance, D.A.B.; Drasar, B.S.; Tovey, G. Effects of Burkholderia pseudomallei and other species on eukaryotic cells in tissue culture. Microbios 1998, 96, 71-93.
14. Jones, A.L.; Beveridge, T.J.; Woods, D.E. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 1996, 64, 782-790.
15. Kespichayawattana, W.; Rattanachetkul, S.; Wanun, T.; Utaisincharoen, P.; Sirishinha, S. Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect. Immun. 2000, 68, 5377-5384.
16. Santanirand, P.; Harley, V.S.; Dance, D.A.B.; Drasar, B.S.; Bancroft, G.J. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 1999, 67, 3593-3600.
17. Ulett, G.C.; Ketheesan, N.; Hirst, R.H. Macrophage-lymphocyte interactions mediate anti-Burkholderia pseudomallei activity. FEMS Immunol. Med. Mic. 1998, 21, 283-286.
18. Ulett, G.C.; Ketheesan, N.; Hirst, R.H. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect. Immun. 2000, 68, 2034-2042.
19. Cooper, A.M.; Dalton, D.K.; Stewart, T.A. Disseminated tuberculosis in gamma interferon-disrupted mice. J. Exp. Med. 1993, 178, 2243-2247.
20. Muotiala, A.; Mäkelä, P.H. The role of IFN-γ in murine Salmonella typhimurium infection. Microb. Pathogenesis. 1990, 8, 135-141.
21. Brett, P.J.; Woods, D.E. Pathogenesis of and immunity to melioidosis. Acta Trop 2000, 74, 201-210.
22. Brett, P.J.; Mah, D.C.W.; Woods, D.E. Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect. Immun. 1994, 62, 1914-1919.
23. Brett, P.J.; Woods, D.E. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 1996, 64, 2824-2828.
24. Bryan, L.E.; Wong, S.; Woods, D.E.; Dance, D.A.B.; Chaowagul, W. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can. J. Infect. Dis. 1994, 5, 170-178.
25. Zeitlin, L.; Cone, R.A.; Whaley, K.J. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg. Infect. Dis. 1999, 5, 54-64.
26. Zeitlin, L.; Cone, R.A.; Moench, T.R.; Whaley, K.J. Preventing infectious disease with passive immunization. Microbes Infect 2000, 2, 701-708.
27. Steinmetz, I.; Nimtz, M.; Wray, V.; Häussler, S.; Reganzerowski, A.; Brenneke, B. Exopolysaccharides of Burkholderia pseudomallei. Acta Trop 2000, 74, 211-214.
28. Otterbein, C.-K.; Splettstößer, W.D.; Linde, H.-J.; Grunow, R.; Wolf, H.; Finke, E.-J.; Neubauer, H. Production and Characterization of a Monoclonal Antibody reactive with a 64kDa Somatic Antigen of Burkholderia cepacia. Hybridoma 1998, 17, 143-150.
29. Gauthier, Y.P.; Thibault, F.M.; Paucod, J.C.; Vidal, D.R. Protease production by Burkholderia pseudomallei and virulence in mice. Acta Trop 2000, 74, 215-220.
30. Gauthier, Y.P.; Hagen, R.M.; Brochier, G.; Neubauer, H.; Splettstoesser, W.D.; Finke, E-J.; Vidal, D.R. Study on the pathophysiology of experimental Burkholderia pseudomallei infection in mice. FEMS Immunol. Med. Mic. 2001, 30, 53-63.
31. Hoppe, I.; Brenneke, B.; Rohde, M.; Kreft, A.; Häubler, S.; Reganzerowski, A.; Steinmetz, I. Characterization of a murine model of melioidosis: comparison of different strains of mice. Infect. Immun. 1999, 67, 2891-2900.
32. Inglis, T.J.; Golledge, C.L.; Clair, A.; Harvey, J. Case report: recovery from persistent septicemic melioidosis. Am. J. Trop. med. Hyg. 2001, 65, 76-82.
33. Suputtamongkol, Y.; Rajchanuvong, A.; Chaowagul, W.; Dance, D.A.B.; Smith, M.D.; Wuthiekanum, V.; Walsh, A.L.; Pukrittayakamee, S.; White, N. J. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin. Infect. Dis. 1994, 19, 846-853.
34. Russel, P.; Eley, S.M.; Ellis, J.; Green, M.; Bell, D.L.; Kenny, D.J.; Titball, R.W. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J. Antimicrob. Chemoth. 2000, 45, 813-818.
35. Casadevall, A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 2002, 8, 833-843.
36. Dunn, D.L.; Ewald, D.C.; Chandan, N.; Cerra, F.B. Immunotherapy of Gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. Arch. Surg. 1986, 121, 58-62.
37. Gaglani, M.J.; Baker, C.J.; Edwards, M.S. Contribution of antibody to neutrophil-mediated killing of Enterococcus faecalis. J. Clin. Immunol. 1997, 17, 478-484.
38. Perry, M.P.; MacLean, L.L.; Schollaardt, T.; Bryan, L.E.; Ho, M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect. Immun. 1995, 63, 3348-3352.
39. Steinmetz, I.; Rhode, M.; Brenneke, B. Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Infect. Immun. 1995, 63, 3959-3965.
40. Ho, M.; Schollaardt, T.; Smith, M.D.; Perry, M.B.; Brett, P.J.; Chaowagul, W.; Bryan, L. E. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 1997, 65, 3648-3653.
41. Huebner, J.; Quaas, A.; Krueger, W.A.; Goldman, D.A.; Pier, G.B. Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci. Infect. Immun. 2000, 68, 4631-4636.
42. Collins, M.S.; Ladehoff, D.; Mehton, N.S. Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens. In Pseudomonas aeruginosa in Human Diseases; Homma, J. Y., Tanimoto, H., Holder, I.A., Hoiby, N., Döring, G., Eds.; Karger: Basel, 1991, 44; 185-195.
43. Leakey, A.L.; Ulett, G.C.; Hirst, R.G. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb. Pathogenesis. 1998, 24, 269-275.
44. Veljanov, D.; Vesselinova, A.; Nikolova, S.; Najdenski, H.; Kussovski, V.; Markova, N. Experimental melioidosis in inbred mouse strains. Zbl. Bakt. 1996, 283, 351-359.
45. Liu, B.; Koo, G.C.; Yap, E.H.; Chua, K.L.; Gan, Y- H. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect. Immun. 2002, 70, 504-511.
46. Dumont, F.J. Modulation of Th1 and Th2 responses for immunotherapy. Expert Opin. Ther. Patents. 2002, 12, 1-27.
47. Raupach, B.; Kaufmann, S.H.E. Immune responses to intracellular bacteria. Curr. Opin. Immunol. 2001, 13, 417-428.
48. Gately, M.K.; Renzetti, L.M.; Magram, J.; Stern, A.S.; Adorini, L.; Gubler, U.; Presky, D.H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic mmune responses. Annu. Rev. Immunol. 1998, 16, 495-521.
49. Cooper, A.M.; Dalton, D.K.; Stewart, T.A. Disseminated tuberculosis in gamma interferon-disrupted mice. J. Exp. Med. 1993, 178, 2243-2247.
50. Barnes, J.L.; Ulett, G.C.; Ketheesan, N.; Summers, P.M.; Hirst, R.G. Induction of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia pseudomallei infection. Immunol. Cell Biol. 2001, 79, 490-501.
51. Miyagi, K.; Kawakami, K.; Saito, A. Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect. Immun. 1997, 65, 4108-4113.
52. Utaisincharoen, P.; Tangthawomchaikul, N.; Kespichayawattana, W.; Chaisuriya, P.; Sirisinha, S. Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol. Immunol. 2001, 45, 307-313.
53. Car, B.D.; Eng, V.M.; Schnyder, B.; Ozmen, L.; Huang, S.; Gallay, P.; Heumann, D.; Aguet, M.; Ryffel, B. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 1994, 179, 1437-1444.
54. Heremans, H.; VanDamme, J.; Dillen, C.; Dijkmans, R.; Billiau, A. Interferon gamma, a mediator of lethal polysaccharide-induced Schwartzman-like shock reactions in mice. J. Exp. Med. 1990, 171, 1853-1869.
55. Friedland, J.S.; Supputamongkol, Y.D.; Remick, G.; Chaowagul, W.; Strieter, R.M; Kunkel, S.L; White, N.J.; Griffin, G.E. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect. Immun. 1992, 60, 2402-2408.
56. Lauw, F.N.; Simpson, A.J.H.; Prins, JM.; Van Devente, S.J.H.; Chaowagul, W.; White, N.J.; Van der Poll, T. The CXC Chemokines gamma interferon (IFN-γ)-inducible protein 10 and monokine induced by IFN-γ are released during severe melioidosis. Infect. Immun. 2000, 68, 3888-3893.
57. Simpson, A.J.H.; Smith, M.D.; Weverling, G.J.; Suputtamongkol, Y.; Angus, B.J.; Chaowagul, W.; White, N.J.; van Deventer, S.J.H.; Prins, J.M. Prognostic value of cytokine concentrations (tumor necrosis factor-α, interleukin-6, and interleukin-10) and clinical parameters. J. Infect. Dis. 2000, 181, 621-625.
58. Biron, C.A.; Gazzinelli, R.T. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 1995, 7, 485-496.
59. Hack, C.E.; Aarden, L.A.; Thijs, L.G. Role of cytokines in sepsis. Adv. Immunol. 1997, 66, 101-195.